G
Gyre Therapeutics Inc. (GYRE)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
$4.39
+0.08 (+1.86%)
Market Cap: $471.74M
Last updated: Nov 17, 2026 at 11:05 AM ET
Gyre Therapeutics Inc. (GYRE) Valuation Multiples
Gyre Therapeutics (GYRE) trades at 3.8x sales and 4.3x book value. Its P/B of 4.3x is above its 10-year median of 0.4x. Its forward P/E is 188.7x.
Current Multiples
| Multiple | Value |
|---|---|
| P/E (trailing) | N/A |
| Forward P/E | 188.7x |
| Price to sales | 3.8x |
| Price to book | 4.3x |
| PEG | N/A |
| FCF yield | -5.3% |
Historical Medians
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/B | 4.3x | N/A | 0.4x |
Valuation History
Over the 7 of the 10 year ends shown that have a P/S, its P/S ranged from 1.0x in 2021 to 35.8x in 2017.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $7.06 | 84.8x | 5.4x | 6.9x |
| 2024 | $12.10 | 156.3x | 10.2x | 19.5x |
| 2023 | $25.69 | N/A | N/A | N/A |
| 2022 | $7.91 | N/A | 5.1x | 0.6x |
| 2021 | $3.60 | N/A | 1.0x | 0.1x |
| 2020 | $24.88 | N/A | 1.2x | 0.4x |
| 2019 | $26.85 | N/A | N/A | 0.3x |
| 2018 | $31.10 | N/A | N/A | 0.2x |
| 2017 | $53.77 | N/A | 35.8x | 0.6x |
| 2016 | $38.42 | N/A | 6.0x | 0.1x |
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About GYRE
What is GYRE's forward P/E ratio?
Gyre Therapeutics has a forward P/E ratio of 188.7x.
Is GYRE stock overvalued?
GNG's valuation label for GYRE is Undervalued.
What is GYRE's price to sales ratio?
Gyre Therapeutics has a price to sales ratio of 3.8x.
GYRE pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors